Skip to main content
TipRanks
Go Ultimate75% OFF

Uscom Limited (UCM) AI Stock Analysis

0 Followers
AU:UCM

Uscom Limited

(ASX:UCM)

Select Model
Rating:43Neutral
Price Target:AUD 0.01â–²(0.00% Upside)
Action:reiterated
Date:10/19/25

Uscom Limited's overall stock score of 43 reflects significant challenges, primarily driven by poor financial performance with declining revenues, persistent losses, negative equity, and high leverage. Technical indicators also suggest a bearish trend despite oversold conditions, while valuation remains neutral due to negative earnings and lack of dividends. Financial health is the most critical concern for investors.

Positive Factors
Product OfferingUscom's focus on innovative non-invasive monitoring devices, like the Uscom 1A, positions it well in the growing healthcare technology sector, providing a competitive edge in improving patient outcomes.
Negative Factors
Financial InstabilityThe negative equity and poor debt-to-equity ratio highlight potential solvency issues, which could limit the company's ability to invest in growth and innovation.

Uscom Limited (UCM) vs. iShares MSCI Australia ETF (EWA)

-5%0%5%10%15%20%25%AU:UCM0.00%EWA+16.05%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 3.12M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-1.6
Beta (1Y)
-0.71
Revenue Growth
-52.22%
EPS Growth
44.79%
Country
Australia
Employees
35
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Uscom Limited Business Overview & Revenue Model

Company Description

Globally, Uscom Limited specializes in the creation, production, and distribution of non-intrusive medical instruments for assessing heart and lung health. Its product portfolio includes the USCOM 1A, a device utilizing Doppler ultrasound to non-inva...

How the Company Makes Money

Uscom generates revenue through the sale of its medical devices, primarily the Uscom 1A, to hospitals, clinics, and healthcare providers. The company also benefits from recurring revenue generated through service contracts, maintenance agreements, an...

Uscom Limited Financial Statement Overview

Summary

Uscom Limited's financial performance is weak, with a sharp revenue decline of 28.98%, persistent net losses (net profit margin of -128.07%), negative equity, high leverage (debt-to-equity ratio of -59.22), and negative cash flows despite a 79.47% improvement in free cash flow growth. While gross margin remains strong at 86.48%, the overall financial health signals significant risks.

Income Statement

15Very Negative

Balance Sheet

10Very Negative

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue1.22M2.58M3.73M2.66M2.51M3.86M
Gross Profit104.60K2.23M3.12M-1.03M-1.21M781.70K
EBITDA-2.69M-2.81M-1.51M-2.50M-1.84M-833.84K
Net Income-1.29M-3.30M-2.07M-2.59M-1.97M-924.24K
Balance Sheet
Total Assets460.89K3.25M5.13M5.18M7.99M5.33M
Cash, Cash Equivalents and Short-Term Investments1,872966.66K2.52M2.18M4.70M1.71M
Total Debt21.09K2.26M989.28K1.09M1.31M1.43M
Total Liabilities278.09K3.29M2.07M2.14M2.06M2.26M
Stockholders Equity182.80K-38.22K3.06M3.04M5.94M3.08M
Cash Flow
Free Cash Flow-2.82M-2.72M-1.22M-1.58M-1.08M21.63K
Operating Cash Flow-2.81M-2.71M-1.16M-1.42M-967.51K54.98K
Investing Cash Flow-44.62K-68.78K-57.55K-151.94K-115.31K-33.35K
Financing Cash Flow691.22K1.21M1.57M-952.96K4.05M-281.87K

Uscom Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price0.01

Price Trends

50DMA0.01Negative
100DMA0.01Negative
200DMA0.01Negative

Market Momentum

MACD-0.00Neutral
STOCH-66.67Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:UCM, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and above the 200-day MA of 0.01, indicating a bearish trend. The MACD of -0.00 indicates Neutral momentum. The RSI at is Neutral, neither overbought nor oversold. The STOCH value of -66.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:UCM.

Uscom Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:UCM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:CYCAU:CYC47NeutralAUD 60.04M-2.98-62.14%―12.05%-31.71%
AU:4DXAU:4DX46NeutralAUD 1.32B-5.55-288.42%―20.64%-457.40%
AU:UCMAU:UCM43NeutralAUD 3.12M-1.56-1788.57%―-52.22%44.79%
AU:IMRAU:IMR41NeutralAUD 482.39M-7.91-184.93%―-68.64%36.40%
AU:EBRAU:EBR39UnderperformAUD 131.05M-1.15-143.78%―1051.49%30.45%
AU:IPDAU:IPD39UnderperformAUD 14.66M-0.34-259.31%―14.85%-1.74%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%AU:UCMAU:IPDAU:CYCAU:4DXAU:EBRAU:IMRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:UCM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:UCMUscom Limited0.010.000.00%
AU:IPDImpedimed Limited0.01-0.02-62.16%
AU:CYCCyclopharm Limited0.48-0.19-28.27%
AU:4DX4DMedical Ltd2.190.7147.97%
AU:EBREBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh0.15-0.85-84.52%
AU:IMRImricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh1.34-0.02-1.10%

Uscom Limited Corporate Events

Uscom Limited Announces FY2025 Results and Strategic Plans for FY2026

Nov 27, 2025

Uscom Limited, a leader in medical technology, has announced its FY2025 results and outlined drivers for FY2026. The company has achieved significant milestones, including global clinical adoption and sales in 52 countries, supported by over 1,200 pe...

Uscom Limited Approves Disposal of Main Undertaking

Nov 7, 2025

Uscom Limited has announced the results of a recent meeting where a resolution was passed to approve the disposal of the company’s main undertaking. The resolution was decided by a poll, with 59.86% voting in favor and 40.14% voting against, indicati...

Uscom Limited Announces Asset Sale Amid Financial Challenges

Oct 31, 2025

Uscom Limited is facing a challenging financial situation, exacerbated by global events such as COVID-19, geopolitical tensions, and trade wars, which have significantly impacted its revenue and led to consecutive years of losses. The company has dec...

Uscom Limited Faces Q1 Challenges Amid Global Economic Uncertainty

Oct 31, 2025

Uscom Limited reported a challenging first quarter with a decrease in customer receipts and cash on hand, attributed to global economic uncertainties such as US tariff wars and shifts in European public spending. Despite these challenges, the company...

Uscom Limited Announces Digital-First Annual General Meeting

Oct 27, 2025

Uscom Limited has announced its Annual General Meeting of Shareholders, scheduled for November 27, 2025, in Sydney. The company will not send physical copies of the meeting notice, opting instead for electronic distribution. Shareholders are encourag...

Uscom Limited Announces 2025 AGM and Key Resolutions

Oct 27, 2025

Uscom Limited has announced its 2025 Annual General Meeting (AGM) scheduled for November 27, 2025, in Sydney. Key agenda items include the consideration of the company’s financial report for the year ending June 30, 2025, the adoption of the remunera...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 19, 2025